Stocks
Johnson & JohnsonJNJ
NYSEHealthcarePharmaceuticals$241.52-0.21%
A diversified healthcare conglomerate, the company operates across innovative medicines and medical technology, following the 2023 separation of its consumer health business into Kenvue. Its pharmaceutical segment focuses on oncology, immunology, neuroscience, and cardiovascular therapies, while the medtech unit produces surgical, orthopedic, and vision products used globally. Investors monitor its drug pipeline, litigation exposure, and durable cash flows, which support one of the longest-running dividend track records in the market.
Market Cap: $582.0B52W Range: $141.50 – $251.71
Congressional Interest in Johnson & Johnson (JNJ)
23 members of Congress have disclosed 50 trades in Johnson & Johnson (JNJ), a Healthcare company. The buy/sell breakdown shows 21 purchases versus 29 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
23
Buys
21
Sells
29
Who in Congress Is Trading JNJ?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-07-28 | Thomas MacArthur | buy | $1K – $15K |
| 2017-07-27 | David P. Roe | buy | $1K – $15K |